General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
7 Stocks to Sell as Banks Melt Down | investorplace.com • |
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study | zacks.com • |
Nabriva's stock is up after sharing antibiotic news | marketwatch.com • |
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript | seekingalpha.com • |
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022 | globenewswire.com • |
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today? | investorplace.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-08-02 | 2023-06 | 0 | N/A | N/A | N/A |
2023-05-22 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-17 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-10 | 2022-09 | -4.03 | N/A | N/A | N/A |
2022-08-03 | 2022-06 | -5 | N/A | N/A | N/A |
2022-05-05 | 2022-03 | -4.75 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2020-12-07 | Morgan Stanley | Upgrade | Equal-Weight | |
2020-04-09 | H.C. Wainwright | Downgrade | Buy | Neutral |
2020-04-09 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2020-04-08 | Needham | Downgrade | Buy | Hold |
2020-03-19 | Wedbush | Downgrade | Outperform | Neutral |
2020-03-17 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-08-01 | BROOM COLIN | Director | 36.52K | Sale |
2022-08-01 | BURGESS DANIEL D | Director | 10.38K | Sale |
2022-08-01 | CORRIGAN MARK | Director | 7.20K | Sale |
2022-08-10 | DOLAN DANIEL | Chief Financial Officer | 0.00 | Conversion of Exercise of derivative security |
2022-08-10 | GELONE STEVEN P | President | 0.00 | Conversion of Exercise of derivative security |
2022-08-10 | GUICO-PABIA CHRISTINE J | Officer | 0.00 | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | Values First Advisors, Inc. | 26.68K | 41.36K | 0.83% |
2023-03-30 | Renaissance Technologies, LLC | 23.36K | 36.21K | 0.73% |
2023-03-30 | Frazier Life Sciences Management, L.P. | 17.02K | 26.39K | 0.53% |
2023-03-30 | Citadel Advisors Llc | 11.61K | 17.99K | 0.36% |
2023-03-30 | Morgan Stanley | 4.11K | 6.37K | 0.13% |
2023-03-30 | Advisor Group Holdings, Inc. | 2.01K | 3.11K | 0.06% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-02-27 | Fidelity NASDAQ Composite Index Fund | 1.71K | 2.65K | 0.05% |
Split | Date |
---|---|
1 : 25 | 2022-09-16 |
1 : 10 | 2020-12-03 |
10 : 1 | 2017-06-26 |
This company is out of Ireland which most of the big Pharmaceutical companies are located in some form. This should take off as proposed!
Ouch its like getting a shot in the back side
$NBRV 23k shares... its bumpy but I trust it will pay off.
Loading up
Buy next months options! If you still own this months
And that’s why it’s at 2.31
Switching to buy yippie
Can someone acquire them already?!
Oh No strong sell now
Ahhhhh a true power hour
Nabriva expects XENLETA will be available through major U.S. specialty distributors in mid-September 2019. XENLETA will have a wholesale acquisition (WAC) price of $205 per IV patient treatment day and $275 per oral patient treatment day.
Still strong buy at 2.33 (hope we get a sign)
It’s going down *
Ton of volume pre market